ESMO 2023

[Palex80]

Hello!

ESMO 2023 will be held in Madrid, 20-24 October 2023.

Is anyone coming? I will be there, reach out per DM if you want to meet up!

I will be posting abstracts here, once they become available. I heard rumors about several interesting stuff that will be presented.

---

Members don't see this ad.

 

[grenz]

Hello!

ESMO 2023 will be held in Madrid, 20-24 October 2023.

Is anyone coming? I will be there, reach out per DM if you want to meet up!

I will be posting abstracts here, once they become available. I heard rumors about several interesting stuff that will be presented.

PREOPANC-2?

 

[Palex80]

PREOPANC-2?

Possibly. Readout was supposed to happen in September 2023.

https://x.com/MarcBesselink/status/1666374801487699969

But perhaps they want to present at ASCO GI 2024, which is 3 months later?

 

[Palex80]

Abstract titles are out! Here's a selection of rad-onc related stuff.


Lung:

LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer​

1291O - Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): a prospective multicentre, open-label, randomised, controlled trial.​

1988MO - Recruitment discontinuation in TREASURE trial (Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease) due to unexpected safety data​

GU:

1764O - Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Final Results of RADICALS RT Randomised Controlled Trial [NCT00541047]​

1770O - Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): an individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium​

LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): a randomised, phase 2 trial: ENZA-p (ANZUP 1901)​

LBA13 - Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)​

GI:

LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial​

LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)​

LBA26 - Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial​

LBA83 - Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial​

Gyn:

LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial​

LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study​

H&N:

853O - OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase 2 trial​

 

[Palex80]

PREOPANC-2?

PREOPANC-2 will be presented!

 

[grenz]

Abstract titles are out! Here's a selection of rad-onc related stuff.


Lung:

LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer​

1291O - Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): a prospective multicentre, open-label, randomised, controlled trial.​

1988MO - Recruitment discontinuation in TREASURE trial (Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease) due to unexpected safety data​

GU:

1764O - Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Final Results of RADICALS RT Randomised Controlled Trial [NCT00541047]​

1770O - Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): an individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium​

LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): a randomised, phase 2 trial: ENZA-p (ANZUP 1901)​

LBA13 - Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)​

GI:

LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial​

LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)​

LBA26 - Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial​

LBA83 - Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial​

Gyn:

LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial​

LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study​

H&N:

853O - OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase 2 trial​

Wow these are some great trial concepts. Will be really interesting to see the results!

 

[Ray D. Ayshun]

Mods, please close this thread about clinical radiation oncology and ban Palex.

 

[BobbyHeenan]

Wow these are some great trial concepts. Will be really interesting to see the results!

Agree.

@Palex80 - thank you for posting. these ESMO presentations often aren't on my radar in the emails or in my rad onc twitter feed.

 

[HolySmokes]

Mods, please close this thread about clinical radiation oncology and ban Palex.

I don't understand, what does this have to do about the job market??

 

[communitydoc13]

Abstract titles are out! Here's a selection of rad-onc related stuff.


Lung:

LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer​

1291O - Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): a prospective multicentre, open-label, randomised, controlled trial.​

1988MO - Recruitment discontinuation in TREASURE trial (Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease) due to unexpected safety data​

GU:

1764O - Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Final Results of RADICALS RT Randomised Controlled Trial [NCT00541047]​

1770O - Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): an individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium​

LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): a randomised, phase 2 trial: ENZA-p (ANZUP 1901)​

LBA13 - Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)​

GI:

LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial​

LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)​

LBA26 - Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial​

LBA83 - Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial​

Gyn:

LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial​

LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study​

H&N:

853O - OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase 2 trial​

Embarrassingly good listing of trials. How many were performed in the US?

 

[Palex80]

Forget about the abstracts! Is anyone coming to Madrid?

 

[Doctorer]

ASTRO is doing us a favor this year. We don't have to waste our time going to any clinical trials sessions, give us more time to enjoy San Diego instead of that stupid Riverwalk for the nth time.

 

[evilbooyaa]

Thanks for posting, Palex. Very interesting set of results to keep an eye on, lots of potentially practice changing things here.

 

[Palex80]

Non-LBAs are now published.

1291O - Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): a prospective multicentre, open-label, randomised, controlled trial.​

Looks negative.

1988MO - Recruitment discontinuation in TREASURE trial (Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease) due to unexpected safety data
5/23 patients with Grade 5 toxicity in IO arm, although not clearly related to RT.

1764O - Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Final Results of RADICALS RT Randomised Controlled Trial [NCT00541047]​

Nothing new here. Adjuvant RT is as good as salvage RT. Freedom from metastatic failure at 10 years is very high in RADICALS (>90%) in both arms.

1770O - Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): an individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium​

Patients with at least two HR-factors or cN1 seem to perform the poorest and are candidates for treatment intensification.

853O - OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase 2 trial​

It seems that giving SABR alone and delaying chemotherapy leads to not-significantly worse PFS, same OS and better QoL. It's only 70 patients in the trial, but the concept is interesting.

 

[theradiator]

Non-LBAs are now published.

1291O - Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7 – IFCT 1401): a prospective multicentre, open-label, randomised, controlled trial.​

Looks negative.

1988MO - Recruitment discontinuation in TREASURE trial (Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease) due to unexpected safety data
5/23 patients with Grade 5 toxicity in IO arm, although not clearly related to RT.

1764O - Timing of Radiotherapy (RT) After Radical Prostatectomy (RP): Final Results of RADICALS RT Randomised Controlled Trial [NCT00541047]​

Nothing new here. Adjuvant RT is as good as salvage RT. Freedom from metastatic failure at 10 years is very high in RADICALS (>90%) in both arms.

1770O - Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): an individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium​

Patients with at least two HR-factors or cN1 seem to perform the poorest and are candidates for treatment intensification.

853O - OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase 2 trial​

It seems that giving SABR alone and delaying chemotherapy leads to not-significantly worse PFS, same OS and better QoL. It's only 70 patients in the trial, but the concept is interesting.

Great summary

 

[Palex80]

That's weird!

Russian hackers?


Anyways, here we go!

LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer​

Interesting design. They gave 3 x 8 Gy to the primary (only!) hoping to cause immunomodulation during neoadjuvant IO-chemo for mostly stage III NSCLC. 76% nodal clearance.



LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): a randomised, phase 2 trial: ENZA-p (ANZUP 1901)
bPFS increased through combination

LBA13 - Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)​

rPFS superior with lutetium vs. ARSI.


LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial
300 patient trial. Non-inferior DFS and OS in active surveillance arm (although numerically inferior), HRQOL superior with active surveillance.
Surgeons are already panicking...

LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)​

Superior pCR with SCRT followed by chemotherapy+IO compared to LCRT.

LBA26 - Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial​

Non-inferiortity statistically not confirmed due to extremely low rates of local recurrence in both arms (below 4%). I think we are out of business in low-risk cT3 rectal cancer, if one does not opt for organ preservation.

LBA83 - Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial​

WOW! Folfirinox demonstrates almost identical rates of OS and resectability with gemcitabine-based RCT. No superiority for Folfirinox. 375 patients in the trial. You gotta love the Dutch!


LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial
Induction chemotherapy (6 weeks of carbo/taxol) prior to cisplatin-based RCT increases PFS and OS. Mostly stage II disease on trial, 500 patients.
This is practice-changing!

LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study​

PFS improved, OS shows trend for improvement with IO following chemotads in this 1000 patient-trial. OS may not be mature yet, not many events.

 

[NotMattSpraker]

1988MO - Recruitment discontinuation in TREASURE trial (Thoracic RadiothErapy with Atezolizumab in Small cell lUng canceR Extensive disease) due to unexpected safety data
5/23 patients with Grade 5 toxicity in IO arm, although not clearly related to RT.

This is sort of a big deal if we think it has harm over chemoIO alone. Were they giving 30/10 thoracic RT?

853O - OMITting frontline chemotherapy in head and neck cancer (HNSCC) patients with 1-3 oligometastases using stereotactic ablative radiotherapy (SABR), the GORTEC 2014-04 “OMET” randomized phase 2 trial​

It seems that giving SABR alone and delaying chemotherapy leads to not-significantly worse PFS, same OS and better QoL. It's only 70 patients in the trial, but the concept is interesting.

This concept should be a bigger deal!

 

[Palex80]

This is sort of a big deal if we think it has harm over chemoIO alone. Were they giving 30/10 thoracic RT?

Yes, 10 x 3 Gy.
I agree.

 

[DoctwoB]

Thanks for posting.

For PSMA-fore trial was Lu compared to first use of ARSI? Or comparing to switching to second ARSI from first ARSI?

Not sure which one I'm rooting for, as in both cases it's hard to know what to do with the trial.

If the first; who is letting patients progress to castrate resistance without them being on an ARSI?

If the second, why are we comparing to a second ARSI and not docetaxel?

 

[ramsesthenice]

View attachment 377832



That's weird!

Russian hackers?


Anyways, here we go!

LBA60 - Stereotactic body radiation therapy with sequential immunochemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer​

Interesting design. They gave 3 x 8 Gy to the primary (only!) hoping to cause immunomodulation during neoadjuvant IO-chemo for mostly stage III NSCLC. 76% nodal clearance.



LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): a randomised, phase 2 trial: ENZA-p (ANZUP 1901)
bPFS increased through combination

LBA13 - Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore)​

rPFS superior with lutetium vs. ARSI.


LBA75 - Neoadjuvant chemoradiotherapy followed by surgery versus active surveillance for oesophageal cancer (SANO-trial): a phase-III stepped-wedge cluster randomised trial
300 patient trial. Non-inferior DFS and OS in active surveillance arm (although numerically inferior), HRQOL superior with active surveillance.
Surgeons are already panicking...

LBA25 - Neoadjuvant short-course radiotherapy followed by camrelizumab plus chemotherapy versus long-course chemoradiotherapy followed by chemotherapy in locally advanced rectal cancer: a randomized phase III trial (UNION)​

Superior pCR with SCRT followed by chemotherapy+IO compared to LCRT.

LBA26 - Neoadjuvant Chemotherapy with CAPOX versus Chemoradiation for Locally Advanced Rectal Cancer with Uninvolved Mesorectal Fascia (CONVERT): Final Results of a Phase III Trial​

Non-inferiortity statistically not confirmed due to extremely low rates of local recurrence in both arms (below 4%). I think we are out of business in low-risk cT3 rectal cancer, if one does not opt for organ preservation.

LBA83 - Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial​

WOW! Folfirinox demonstrates almost identical rates of OS and resectability with gemcitabine-based RCT. No superiority for Folfirinox. 375 patients in the trial. You gotta love the Dutch!


LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial
Induction chemotherapy (6 weeks of carbo/taxol) prior to cisplatin-based RCT increases PFS and OS. Mostly stage II disease on trial, 500 patients.
This is practice-changing!

LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study​

PFS improved, OS shows trend for improvement with IO following chemotads in this 1000 patient-trial. OS may not be mature yet, not many events.

CONVERT largely confirms what we know from PROSPECT. Time will tell, but I practice at a high volume academic center and our surgeons have been on the endoscopic surveillance after TNT train for a few years. I can think of 2 people who have opted for anything that mandates surgery in that time. Sucked for me in a way. I had a pretty cool trial opened that was based on the old paradigm and I had to shut it down and revise it significantly to allow watch and wait (which meant changing the primary endpoint). We had 90% enrollment of eligible subjects before our surgeons started offering to consider watch and wait after TNT. Then I went 16 months with 0 enrollments. And patients were clear about why. The trial required surgery regardless of response to therapy. If you have a balanced discussion about omitting radiation or potentially omitting surgery, both of which are now in the NCCN algorithm as of the July update, I doubt you will see radiation go anywhere.

The QOL data back up w/w over omitting radiation well. Bothersome symptoms consistent with LAR syndrome are present in about half of surgical patients. Analyses from the Brazilian cohorts and MSKCC are closer to 25% in w/w patients. Which…maybe LAR syndrome wasn’t all from surgery? But still looks favorable.

 

[Palex80]

Thanks for posting.

For PSMA-fore trial was Lu compared to first use of ARSI? Or comparing to switching to second ARSI from first ARSI?

Not sure which one I'm rooting for, as in both cases it's hard to know what to do with the trial.

If the first; who is letting patients progress to castrate resistance without them being on an ARSI?

If the second, why are we comparing to a second ARSI and not docetaxel?

Patients switched from one ARSI to another in the standard arm. Yes, bad design.

 

[mheat3]

Patients switched from one ARSI to another in the standard arm. Yes, bad design.

Great design if you are Novartis!

 

[evilbooyaa]

LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer. The GCIG INTERLACE trial
Induction chemotherapy (6 weeks of carbo/taxol) prior to cisplatin-based RCT increases PFS and OS. Mostly stage II disease on trial, 500 patients.
This is practice-changing!

LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study​

PFS improved, OS shows trend for improvement with IO following chemotads in this 1000 patient-trial. OS may not be mature yet, not many events.

Need something to improve DM development in locally advanced cervical pts... given OUTBACK negative for consolidative chemotherapy, this is a hopeful step forward.

Interesting to see Pembro succeeded where Durva did not (CALLAS trial)

 

[SneakyBooger]

Standard vs dose reduced chemoradiotherapy in anal cancer: short-term results of the PLATO-ACT4 RCT
Alexandra Gilbert, United Kingdom
Presentation Number: OC-0831

Abstract​

Abstract Title:
Standard vs dose reduced chemoradiotherapy in anal cancer: short-term results of the PLATO-ACT4 RCT

Conclusion​

High 6 month cRR were seen in both arms. sd-IMRT had more RT interruptions and chemotherapy modifications than dr-IMRT. Fewer patients reported overall ≥G3 acute toxicity with dr-IMRT. Most PRO symptoms and function changes had improved to baseline by 6 months, while sexual function had improved for men and women receiving dr-IMRT, it remained poor following sd-IMRT.

 

[grenz]

Standard vs dose reduced chemoradiotherapy in anal cancer: short-term results of the PLATO-ACT4 RCT
Alexandra Gilbert, United Kingdom
Presentation Number: OC-0831

Abstract​

Abstract Title:
Standard vs dose reduced chemoradiotherapy in anal cancer: short-term results of the PLATO-ACT4 RCT

Conclusion​

High 6 month cRR were seen in both arms. sd-IMRT had more RT interruptions and chemotherapy modifications than dr-IMRT. Fewer patients reported overall ≥G3 acute toxicity with dr-IMRT. Most PRO symptoms and function changes had improved to baseline by 6 months, while sexual function had improved for men and women receiving dr-IMRT, it remained poor following sd-IMRT.

View attachment 378019

I’m eagerly awaiting results from this trial. The fact that we treat a small T1N0 anal cancer the same way as a more advanced cancer has never sat well with me

 

[grenz]

https://x.com/fabioschutz78/status/1715373053700428073?s=46&t=fKzMHGgUK_jttOaYQYJXrQ

 

[Mandelin Rain]

https://x.com/fabioschutz78/status/1715373053700428073?s=46&t=fKzMHGgUK_jttOaYQYJXrQ

Unreal.